MaxCyte, Inc. (MXCT): Price and Financial Metrics


MaxCyte, Inc. (MXCT): $4.81

0.36 (+8.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MXCT Stock Price Chart Interactive Chart >

Price chart for MXCT

MXCT Price/Volume Stats

Current price $4.81 52-week high $17.44
Prev. close $4.45 52-week low $4.00
Day low $4.47 Volume 937,400
Day high $4.81 Avg. volume 615,409
50-day MA $5.78 Dividend yield N/A
200-day MA $9.58 Market Cap 488.41M

MaxCyte, Inc. (MXCT) Company Bio


MaxCyte, Inc. operates as a cell-based therapies and life sciences company in the United States and internationally. Its transfection systems include MaxCyte STX, a scalable transfection system that uses flow electroporation technology for the engineering of cells for a range of applications; MaxCyte VLX, an instrument for large volume cell-engineering; and MaxCyte GT, a non-viral cell-engineering technology designed for clinical use. The company also provides single use sterile processing assemblies; and proprietary electroporation buffers; and ExPERT brand series of instruments and consumables, as well as insourcing services. In addition, it develops CARMA, a novel and proprietary technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. The company licenses and sells its instruments and technology; and sells its products to drug developers and biopharmaceutical companies. It has a clinical and commercial license agreement with Allogene Therapeutics, Inc. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.


MXCT Latest News Stream


Event/Time News Detail
Loading, please wait...

MXCT Latest Social Stream


Loading social stream, please wait...

View Full MXCT Social Stream

Latest MXCT News From Around the Web

Below are the latest news stories about Maxcyte Inc that investors may wish to consider to help them evaluate MXCT as an investment opportunity.

MaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022

GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it will release financial results for the fourth quarter and full year of 2021 after the U.S. market close on Tuesday, March 22nd, 2022. Company ma

Yahoo | February 24, 2022

MaxCyte (MXCT) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 17, 2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares o

Yahoo | February 11, 2022

MaxCyte signs strategic platform license to advance tumor infiltrating lymphocyte programs

MaxCyte (MXCT) signed a strategic platform license ((SPL)) with Intima Bioscience, a biotech developing genetically engineered cell therapies for solid tumor cancer.Under the terms of

Seeking Alpha | February 1, 2022

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidatesNEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Bioscience, Inc., a clinical stage biotechnology company develop

Yahoo | February 1, 2022

Read More 'MXCT' Stories Here

MXCT Price Returns

1-mo -10.59%
3-mo -29.16%
6-mo -62.39%
1-year N/A
3-year N/A
5-year N/A
YTD -52.80%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6595 seconds.